Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

HPV Vaccine May Benefit HIV-infected Women

Published: Friday, November 30, 2012
Last Updated: Friday, November 30, 2012
Bookmark and Share
The findings appear in the journal of acquired immune deficiency syndromes.

Women with HIV may benefit from a vaccine for human papillomavirus (HPV), despite having already been exposed to HPV, a study finds.

Although many may have been exposed to less serious forms of HPV, more than 45 percent of sexually active young women who have acquired HIV appear never to have been exposed to the most common high-risk forms of HPV, according to the study from a National Institutes of Health research network.

HPV is the most common sexually transmitted infection in the world. The virus can infect the anal and genital areas, mouth and throat of males and females. High-risk forms of the virus can cause cancer, including cancer of the cervix.

The researchers noted that earlier studies had found many women with HIV were more likely than were women who did not have HIV to have conditions associated with HPV, such as precancerous conditions of the cervix, as well as for cervical cancer.

"Health care providers may hesitate to recommend HPV vaccines after a girl starts having sex," said study first author Jessica Kahn, M.D., M.P.H. of Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine.

Kahn continued, "However, our results show that for a significant number of young women, HPV vaccine can still offer benefits. This is especially important in light of their HIV status, which can make them even more vulnerable to HPV's effects."

The Centers for Disease Control and Prevention recommends HPV vaccination for girls ages 11-26. If an individual has not been exposed to the virus, approved HPV vaccines can protect against four types of the virus.

Two HPV types, HPV-16 and HPV-18, cause 70 percent of cervical cancers. Two others, HPV-6 and HPV-11, cause 90 percent of genital warts.

At the time the women in the study received their first HPV vaccination, the researchers found that 12 percent had an existing HPV-16 infection and 5 percent had an HPV-18 infection.

Because of their HIV status, these women may be more likely to develop cervical cancer or to develop a cancer that is hard to treat, the researchers said.

"Cervical cancer screening for sexually active young women is an important clinical priority, but our findings suggest it is especially so for women at risk of HIV," said study co-author Bill G. Kapogiannis, M.D., of the Pediatric, Adolescent and Maternal AIDS Branch of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), one of six NIH institutes supporting the study.

Drs. Kahn and Kapogiannis conducted the research in collaboration with colleagues at the NICHD and Albert Einstein College of Medicine, New York City; Jefferson Medical College of Thomas Jefferson University, Philadelphia; New York University School of Medicine; Westat, Inc., Rockville, Md.; and the University of Alabama at Birmingham.

The research was conducted at a network of hospitals affiliated with the NICHD-funded Adolescent Medicine Trials Network for HIV/AIDS Interventions.

Also supporting the study were the National Institute on Drug Abuse, National Institute of Mental Health, National Institute of Allergy and Infectious Diseases, National Cancer Institute and National Center for Research Resources.

The researchers analyzed blood and tissue samples from 99 HIV-positive women between 16 and 23 years old who were given an initial vaccination for HPV.

The researchers examined the samples for evidence of an existing HPV infection as well as previous exposure to the virus.

The researchers tested for the presence of 41 of more than 100 existing types of HPV virus, including 13 high-risk types. They found that 75 percent of the women had an existing HPV infection with at least one type, with 54 percent testing positive for a high-risk type.

However, when examining the two types that cause 70 percent of cervical cancers (HPV-16 and HPV-18), the researchers found that nearly half of the women had no existing infection with either type and showed no evidence of exposure to them.

When the researchers tested for each type of HPV individually, they found that nearly 75 percent of the women had no current HPV-18 infection and no evidence of previous exposure. For HPV-16, 56 percent did not have a current infection or previous exposure.

"Even among women who test positive for one type of HPV, the vaccine may effectively prevent infection with others - especially high-risk forms that cause cancer," Dr. Kahn said. "It’s important that doctors don't withhold the vaccine in these cases, thinking that it's too late for a vaccine to be effective."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Antibody Protects Mice from Zika Infection
Researchers develop human-derived antibody protected pregnant mice and their developing fetuses from Zika infection.
Wednesday, November 23, 2016
NIH Researchers Unveil New Wound-Healing Role for Protein-Folding Gene in Mice
The study found that topical treatment of an Hsp60-containing gel dramatically accelerates wound closure in a diabetic mouse model.
Friday, October 28, 2016
Ebola-Affected Countries Receive NIH Support
The National Institutes of Health has established a new program to further research capacity to study Ebola and other epidemics.
Thursday, October 27, 2016
Skin Patch to Treat Peanut Allergy
NIH-funded study suggests peanut protein patch is a safe and convenient method of treatment.
Thursday, October 27, 2016
Sustained SIV Remission Achieved in Monkeys
Experimental treatment boosts monkey immune system to force SIV into sustained remission.
Wednesday, October 26, 2016
NIH Study Determines Key Differences between Allergic and Non-Allergic Dust Mite Proteins
Researchers at NIH have uncovered factors that lead to the development of dust mite allergy and assist in the design of better allergy therapies.
Thursday, October 20, 2016
DNA Vaccines Protect Monkeys Against Zika Virus
Two experimental Zika virus DNA vaccines developed by NIH scientists protected monkeys against Zika infection.
Wednesday, October 05, 2016
Researchers Find a Gap in the Brain’s Firewall Against Parkinson’s Disease
Researchers at NIH have found mouse study that identified a key player in the progression of the disorder.
Saturday, October 01, 2016
Oxygen Can Impair Cancer Immunotherapy
Researchers have identified a mechanism within the lungs where anticancer immune resposnse is inhibited.
Friday, August 26, 2016
New Inflammatory Disease Discovered
NIH researchers have discovered a rare and potentially deadly disease - otulipenia - the mostly affects children.
Tuesday, August 23, 2016
Oral Immunotherapy Is Safe, Effective Treatment for Peanut-Allergic Preschoolers
Study demonstrates the potential of peanut OIT to suppress allergic immune responses to peanut.
Friday, August 12, 2016
Mutations Linked to Immunotherapy Resistance
Researchers uncover mutations in tumors of three patients with advanced melanoma that allowed the tumors to become resistant to the immune checkpoint inhibitor pembrolizumab (Keytruda®).
Tuesday, August 09, 2016
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
Friday, July 29, 2016
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Wednesday, July 27, 2016
NIH Investment Into HIV Research Expands
Funding has been awarded to six research teams to lead collaborative investigations worldwide toward an HIV cure.
Thursday, July 14, 2016
Scientific News
New Regulator of Immune Reaction Discovered
Calcium signal in cell nucleus regulates not only many brain functions but also defence reactions of the immune system.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Cell’s ‘Built-In Circuit’ Help Prevent Tumour Growth
Researchers have created cells with a 'built-in genetic circuit' that inhibits tumour growth.
Factors Behind Suppression of Stem Cell Mobilization Revealed
The findings could lead to improvements in transplantation therapy.
Common Virus Helps Fight Liver Cancer
Reovirus, a cause of childhood colds, stimulates the immune system to kill cancerous cells.
Antibody Protects Mice from Zika Infection
Researchers develop human-derived antibody protected pregnant mice and their developing fetuses from Zika infection.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
T Cell Channel Could Be Targeted to Treat Cancers
Researcher identify ion-channel found within T cells that could be targeted to reduce development of neck and head cancers.
Targeting Pancreatic Cancer
Cutting-edge technology exploits cancer cells’ vulnerabilities to develop new treatments.
A Genome-wide View of Human DNA Viruses
In this study, Duplex sequencing was used to accurately analyse the genome-wide rate of spontaneous mutation of human adenovirus C5 (HAdv5).
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!